Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Thromboembolic disorders, treatment

Under this therapy, menses will continue. The risk of thromboembolic disorders is increased and that of myocardial infarction probably lowered. Hormone treatment can be extended for 10 y or longer. Before menopause, daily calcium intake should be kept at 1 g (contained in 1 L of milk), and 1.5 g thereafter. [Pg.318]

Triflusal, a known antiplatelet agent used in the treatment of thromboembolic disorders, is currently being evaluated for use in Alzheimer disease. It has been shown to inhibit the activation of the mediators of neuroinflammation. [Pg.307]

G. Other applications Lepirudin is also under study for the treatment of myocardial infarction and unstable angina and other thromboembolic disorders requiring parenteral antithrombotic therapy such as disseminated intravascular coagulation, in adults. [Pg.153]

Streptokinase is administered by intravenous or intra-arterial infusion in the treatment of thromboembolic disorders, e.g. pulmonary embolism, deep vein thrombosis and arterial occlusions. It is also used in acute myocardial infarction. [Pg.446]

Thrombolytics (see Table 19.1 , (below)) are used in the treatment of thromboembolic disorders. Thrombolytics activate plasminogen to form... [Pg.697]

Lee, Y.-K. and Player, M.R. (2011) Developments in fector Xa inhibitors for the treatment of thromboembolic disorders. Medicinal Research Reviews, 31, 202-283. [Pg.399]

Fluxum. Opocrin. OP 21-23 Low MW heparin (see Heparin, H-5). Prepd. by H2O2 and Cu(//) acetate degradation of heparin obt. from the intestinal mucosa of pigs. Anticoagulant. Used in the prevention and treatment of thromboembolic and other vascular disorders. Launched 1993 (Italy)... [Pg.806]

Strodium ranelate is restricted to second-line treatment of severe osteoporosis in postmenopausal women at high risk of fracture, and in men at increased risk of fracture. A review of available safety data for strodixun ranelate has raised concern about its cardiovascular safety beyond the already recognised risk of venous thromboembolism. An analysis of randomised controlled trial data has identified an increased risk of serious cardiac disorders, including myocardial infarction [65 ]. [Pg.744]

See other pages where Thromboembolic disorders, treatment is mentioned: [Pg.145]    [Pg.146]    [Pg.178]    [Pg.262]    [Pg.109]    [Pg.614]    [Pg.106]    [Pg.459]    [Pg.221]    [Pg.145]    [Pg.146]    [Pg.518]    [Pg.560]    [Pg.115]    [Pg.132]    [Pg.141]    [Pg.91]    [Pg.200]    [Pg.250]    [Pg.1001]    [Pg.159]    [Pg.214]    [Pg.204]    [Pg.1644]    [Pg.2556]    [Pg.179]    [Pg.184]    [Pg.373]    [Pg.227]    [Pg.364]    [Pg.64]    [Pg.207]    [Pg.168]   


SEARCH



Thromboembolism

Treatments Disorders

© 2024 chempedia.info